In this research, we demonstrated that a selective AP‐1 inhibitor, T‐5224, significantly enhanced the anti‐MM activity of lenalidomide in vitro and in two murine MM models (Figure 8, right panel). Here, JUNB is linked to Miyoshi myopathy.